HMG	hmg	O	O
CoA	coa	S_chemical	O
reductase	reductase	O	O
inhibitors	inhibitors	O	O
.	.	O	O

Current	current	O	O
clinical	clinical	O	O
experience	experience	O	O
.	.	O	O

Lovastatin	lovastatin	S_chemical	O
and	and	O	O
simvastatin	simvastatin	S_chemical	O
are	are	O	O
the	the	O	O
2	2	O	O
best-known	best-known	O	O
members	members	O	O
of	of	O	O
the	the	O	O
class	class	O	O
of	of	O	O
hypolipidaemic	hypolipidaemic	O	O
agents	agents	O	O
known	known	O	O
as	as	O	O
HMG	hmg	O	O
CoA	coa	S_chemical	O
reductase	reductase	O	O
inhibitors	inhibitors	O	O
.	.	O	O

Clinical	clinical	O	O
experience	experience	O	O
with	with	O	O
lovastatin	lovastatin	S_chemical	O
includes	includes	O	O
over	over	O	O
5000	5000	O	O
patients	patients	O	O
,	,	O	O
700	700	O	O
of	of	O	O
whom	whom	O	O
have	have	O	O
been	been	O	O
treated	treated	O	O
for	for	O	O
2	2	O	O
years	years	O	O
or	or	O	O
more	more	O	O
,	,	O	O
and	and	O	O
experience	experience	O	O
with	with	O	O
simvastatin	simvastatin	S_chemical	O
includes	includes	O	O
over	over	O	O
3500	3500	O	O
patients	patients	O	O
,	,	O	O
of	of	O	O
whom	whom	O	O
350	350	O	O
have	have	O	O
been	been	O	O
treated	treated	O	O
for	for	O	O
18	18	O	O
months	months	O	O
or	or	O	O
more	more	O	O
.	.	O	O

Lovastatin	lovastatin	S_chemical	O
has	has	O	O
been	been	O	O
marketed	marketed	O	O
in	in	O	O
the	the	O	O
United	united	O	O
States	states	O	O
for	for	O	O
over	over	O	O
6	6	O	O
months	months	O	O
.	.	O	O

Both	both	O	O
agents	agents	O	O
show	show	O	O
substantial	substantial	O	O
clinical	clinical	O	O
efficacy	efficacy	O	O
,	,	O	O
with	with	O	O
reductions	reductions	O	O
in	in	O	O
total	total	B_chemical	O
cholesterol	cholesterol	S_chemical	O
of	of	O	O
over	over	O	O
30	30	O	O
%	%	O	O
and	and	O	O
in	in	O	O
LDL-cholesterol	ldl-cholesterol	S_chemical	O
of	of	O	O
40	40	O	O
%	%	O	O
in	in	O	O
clinical	clinical	O	O
studies	studies	O	O
.	.	O	O

Modest	modest	O	O
increases	increases	O	O
in	in	O	O
HDL-cholesterol	hdl-cholesterol	O	O
levels	levels	O	O
of	of	O	O
about	about	O	O
10	10	O	O
%	%	O	O
are	are	O	O
also	also	O	O
reported	reported	O	O
.	.	O	O

Clinical	clinical	O	O
tolerability	tolerability	O	O
of	of	O	O
both	both	O	O
agents	agents	O	O
has	has	O	O
been	been	O	O
good	good	O	O
,	,	O	O
with	with	O	O
fewer	fewer	O	O
than	than	O	O
3	3	O	O
%	%	O	O
of	of	O	O
patients	patients	O	O
withdrawn	withdrawn	O	O
from	from	O	O
treatment	treatment	O	O
because	because	O	O
of	of	O	O
clinical	clinical	O	O
adverse	adverse	O	O
experiences	experiences	O	O
.	.	O	O

Ophthalmological	ophthalmological	O	O
examinations	examinations	O	O
in	in	O	O
over	over	O	O
1100	1100	O	O
patients	patients	O	O
treated	treated	O	O
with	with	O	O
one	one	O	O
or	or	O	O
the	the	O	O
other	other	O	O
agent	agent	O	O
have	have	O	O
revealed	revealed	O	O
no	no	O	O
evidence	evidence	O	O
of	of	O	O
significant	significant	O	O
short	short	O	O
term	term	O	O
(	(	O	O
up	up	O	O
to	to	O	O
2	2	O	O
years	years	O	O
)	)	O	O
cataractogenic	cataractogenic	O	S_disease
potential	potential	O	O
.	.	O	O

One	one	O	O
to	to	O	O
2	2	O	O
%	%	O	O
of	of	O	O
patients	patients	O	O
have	have	O	O
elevations	elevations	O	O
of	of	O	O
serum	serum	O	O
transaminases	transaminases	O	O
to	to	O	O
greater	greater	O	O
than	than	O	O
3	3	O	O
times	times	O	O
the	the	O	O
upper	upper	O	O
limit	limit	O	O
of	of	O	O
normal	normal	O	O
.	.	O	O

These	these	O	O
episodes	episodes	O	O
are	are	O	O
asymptomatic	asymptomatic	O	O
and	and	O	O
reversible	reversible	O	O
when	when	O	O
therapy	therapy	O	O
is	is	O	O
discontinued	discontinued	O	O
.	.	O	O

Minor	minor	O	O
elevations	elevations	O	O
of	of	O	O
creatine	creatine	B_chemical	O
kinase	kinase	I_chemical	O
levels	levels	O	O
are	are	O	O
reported	reported	O	O
in	in	O	O
about	about	O	O
5	5	O	O
%	%	O	O
of	of	O	O
patients	patients	O	O
.	.	O	O

Myopathy	myopathy	O	S_disease
,	,	O	O
associated	associated	O	O
in	in	O	O
some	some	O	O
cases	cases	O	O
with	with	O	O
myoglobinuria	myoglobinuria	O	O
,	,	O	O
and	and	O	O
in	in	O	O
2	2	O	O
cases	cases	O	O
with	with	O	O
transient	transient	O	O
renal	renal	O	B_disease
failure	failure	O	I_disease
,	,	O	O
has	has	O	O
been	been	O	O
rarely	rarely	O	O
reported	reported	O	O
with	with	O	O
lovastatin	lovastatin	S_chemical	O
,	,	O	O
especially	especially	O	O
in	in	O	O
patients	patients	O	O
concomitantly	concomitantly	O	O
treated	treated	O	O
with	with	O	O
cyclosporin	cyclosporin	S_chemical	O
,	,	O	O
gemfibrozil	gemfibrozil	O	O
or	or	O	O
niacin	niacin	O	O
.	.	O	O

Lovastatin	lovastatin	S_chemical	O
and	and	O	O
simvastatin	simvastatin	S_chemical	O
are	are	O	O
both	both	O	O
effective	effective	O	O
and	and	O	O
well-tolerated	well-tolerated	O	O
agents	agents	O	O
for	for	O	O
lowering	lowering	O	O
elevated	elevated	O	O
levels	levels	O	O
of	of	O	O
serum	serum	B_chemical	O
cholesterol	cholesterol	S_chemical	O
.	.	O	O

As	as	O	O
wider	wider	O	O
use	use	O	O
confirms	confirms	O	O
their	their	O	O
safety	safety	O	O
profile	profile	O	O
,	,	O	O
they	they	O	O
will	will	O	O
gain	gain	O	O
increasing	increasing	O	O
importance	importance	O	O
in	in	O	O
the	the	O	O
therapeutic	therapeutic	O	O
approach	approach	O	O
to	to	O	O
hypercholesterolaemia	hypercholesterolaemia	O	S_disease
and	and	O	O
its	its	O	O
consequences	consequences	O	O
.	.	O	O

